VIG ETF Climbs 0.5%
Dow Jones2026/10/05 20:36This article was automatically generated using Dow Jones technology. Shares of Vanguard Dividend Appreciation ETF advanced 0.5% to $236.15 Monday on what proved to be an overall positive trading session for the U.S. stock market, with the S&P 500 Index rising 0.7% to 7,773.95. This was the fund's third consecutive day of gains. The ETF's shares closed 4.6% below the 52-week high of $247.45 seen on August 13, 2026. Trading volume was 1,206,448, compared to the 65-day average trading volume of 991,078. As of October 2, the fund's net asset value totaled $234.99 per share. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 05, 2026 16:36 ET (20:36 GMT)
This article was automatically generated using Dow Jones technology.
Shares of Vanguard Dividend Appreciation ETF advanced 0.5% to $236.15 Monday on what proved to be an overall positive trading session for the U.S. stock market, with the S&P 500 Index rising 0.7% to 7,773.95.
This was the fund's third consecutive day of gains.
The ETF's shares closed 4.6% below the 52-week high of $247.45 seen on August 13, 2026.
Trading volume was 1,206,448, compared to the 65-day average trading volume of 991,078.
As of October 2, the fund's net asset value totaled $234.99 per share.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 05, 2026 16:36 ET (20:36 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro: Downside risks with 1.1100 in sight against US Dollar – ING
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
